
- /
- Supported exchanges
- / US
- / AMRX.NYSE
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX NYSE) stock market data APIs
Amneal Pharmaceuticals, Inc. Class A Common Stock Financial Data Overview
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Amneal Pharmaceuticals, Inc. Class A Common Stock data using free add-ons & libraries
Get Amneal Pharmaceuticals, Inc. Class A Common Stock Fundamental Data
Amneal Pharmaceuticals, Inc. Class A Common Stock Fundamental data includes:
- Net Revenue: 2 830 M
- EBITDA: 605 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get Amneal Pharmaceuticals, Inc. Class A Common Stock Earnings data
What’s included:
- Latest Release: 2025-03-31
- EPS/Forecast: 0.1467
Get Amneal Pharmaceuticals, Inc. Class A Common Stock End-of-day data
EOD Historical Data package for
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Amneal Pharmaceuticals, Inc. Class A Common Stock News

Amneal Pharma Gets FDA Approval For Prednisolone Acetate Ophthalmic Suspension
(RTTNews) - Amneal Pharmaceuticals, Inc. (AMRX) Thursday said that the U.S. Food and Drug Administration (FDA) has approved prednisolone acetate ophthalmic suspension, a generic version of Allergan's ...


Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension
Key complex product approval in the Affordable Medicines segment this yearCommercial launch planned for third quarter of 2025 BRIDGEWATER, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuti...

Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension
Amneal Pharmaceuticals LLC Key complex product approval in the Affordable Medicines segment this year Commercial launch planned for third quarter of 2025 BRIDGEWATER, N.J., June 12, 2025 (GLOBE NEWS...

Goldman Sachs initiates coverage on generic drugmakers, sees upside in Teva and Am
Investing.com -- Goldman Sachs initiated coverage on U.S.-listed generic pharmaceutical companies with Buy ratings on Teva Pharmaceutical Industries (NYSE:TEVA) and Amneal Pharmaceuticals (NASDAQ:AMRX...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.